Autor:	Viveka Belathur Kalegowda
Rok vydání:	2016
Předmět:	Eribulin Mesylate Oncology Cancer Research medicine.medical_specialty Mesylate business.industry medicine.disease Metastatic breast cancer chemistry.chemical_compound chemistry Internal medicine Medicine Single agent skin and connective tissue diseases business Eribulin
Zdroj:	Journal of Clinical Oncology. 34:e12524-e12524
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.e12524
Popis:	e12524Background: Single agent Eribulin has been used in management of metastatic breast cancer. We report our experience with Eribulin Mesylate(EM) in metastatic Breast Cancer patients in India. M...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a84aaac89f71e7b974cc76c8e42314df https://doi.org/10.1200/jco.2016.34.15_suppl.e12524 Zobrazit plný text záznamu